UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY

REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 3, 2005

OR

TRANSITION REPORT

PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition

period from________to_______

COMMISSION FILE

NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd

Street, New York, New York 10017

(212) 573-2323

(Registrant's telephone number)

Indicate by check mark whether the registrant (1) has

filed all reports required to be filed by Section 13 or 15(d) of the

Securities Exchange Act of 1934 during the preceding 12 months (or for such

shorter period that the registrant was required to file such reports) and (2)

has been subject to such filing requirements for the past 90 days.

YES X

NO

Indicate by check mark whether the registrant is an

accelerated filer (as defined in Rule 12b-2 of the Exchange Act).

YES X

NO

At August 1, 2005, 7,370,501,376 shares of the

issuer's voting common stock were outstanding.

FORM 10-Q

For the Quarter

Ended

July 3, 2005

Table

of Contents

PART I. FINANCIAL

INFORMATION

Page

Item 1.

Financial Statements:

Condensed

Consolidated Statement of Income for the three months and six months ended July 3,

2005 and June 27, 2004

Condensed

Consolidated Balance Sheet at July 3, 2005 and

December 31, 2004

Condensed

Consolidated Statement of Cash Flows for the six months ended July 3,

2005 and June 27, 2004

Notes to

Condensed Consolidated Financial Statements

Review Report

of Independent Registered Public Accounting Firm

17

Item 2.

Management's

Discussion and Analysis of Financial Condition and Results of Operations

18

Item 4.

Controls and

Procedures

42

PART II. OTHER INFORMATION

Item 1.

Legal

Proceedings

42

Item 2.

Unregistered

Sales of Equity Securities and Use of Proceeds

44

Item 6.

Exhibits

44

Signature

45

PART

I. FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENT OF INCOME

(UNAUDITED)

Three Months Ended

Six Months Ended

(millions

of dollars, except per common share data)

July 3,

2005

June 27,

2004

July 3,

2005

June 27,

2004

Revenues

12,425

12,274

25,516

24,762

Costs

and expenses:

Cost of sales(a)

2,081

1,752

4,272

3,546

Selling, informational and administrative expenses(a)

4,226

4,258

8,311

8,191

Research and development expenses(a)

1,875

1,819

3,639

3,469

Amortization of intangible assets(a)

859

830

1,741

1,653

Merger-related in-process research and development

charges

260

--

262

955

Restructuring charges and merger-related costs

270

289

489

536

Other (income)/deductions - net

(207)

(102)

831

(145)

Income from continuing operations before (benefit)/provision

for taxes on income, and minority interests

3,061

3,428

5,971

6,557

(Benefit)/provision for taxes on income

(413)

582

2,222

1,390

Minority interests

Income from continuing operations

3,472

2,844

3,744

5,163

Discontinued operations:

(Loss)/income from discontinued operations - net

of tax

(9)

17

(22)

30

Gains on sales of discontinued operations - net

of tax

--

41

Discontinued operations - net of tax

(9)

19

19

32

Net income

3,463

2,863

3,763

5,195

Earnings

per common share - Basic:

Income from continuing operations

.47

.38

.51

.69

Discontinued operations - net of tax

--

--

--

--

Net income

.47

.38

.51

.69

Earnings

per common share - Diluted:

Income from continuing operations

.47

.38

.51

.68

Discontinued operations - net of tax

--

--

--

--

Net income

.47

.38

.51

.68

Weighted-average shares used to calculate earnings per

common share:

Basic

7,366

7,574

7,391

7,580

Diluted

7,418

7,664

7,445

7,672

Cash

dividends paid per common share

.19

.17

.38

.34

(a)

Includes

amortization of intangible assets, as disclosed in Note 9B,

Goodwill

and Other Intangible Assets: Other Intangible Assets.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER INC AND SUBSIDIARY

COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEET

(UNAUDITED)

(millions

of dollars)

July 3,

2005*

Dec. 31,

2004**

ASSETS

Current Assets

Cash and cash

equivalents

1,276

1,808

Short-term

investments

13,293

18,085

Accounts

receivable, less allowance for doubtful accounts: 2005 - $220;

2004 - $205

9,316

9,367

Short-term

loans

513

653

Inventories

6,480

6,660

Prepaid

expenses and taxes

2,506

2,939

Assets held for

sale

189

182

Total current assets

33,573

39,694

Long-term

investments and loans

3,247

3,873

Property, plant

and equipment, less accumulated depreciation:

2005 - $8,982; 2004 - $8,534

17,673

18,385

Goodwill

23,627

23,756

Identifiable

intangible assets, less accumulated amortization

29,782

33,251

Other assets,

deferred taxes and deferred charges

4,425

4,725

Total assets

112,327

123,684

LIABILITIES

AND SHAREHOLDERS' EQUITY

Current Liabilities

Short-term

borrowings, including current portion of long-term debt:

2005 - $2,405; 2004 - $907

7,261

11,266

Accounts

payable

2,100

2,672

Dividends payable

1,406

1,418

Income taxes

payable

4,356

1,963

Accrued

compensation and related items

1,469

1,939

Other current

liabilities

5,934

7,136

Liabilities

held for sale

40

64

Total current liabilities

22,566

26,458

Long-term debt

5,517

7,279

Pension benefit

obligations

2,852

2,821

Postretirement

benefit obligations

1,444

1,450

Deferred taxes

on income

11,479

12,632

Other

noncurrent liabilities

3,141

4,766

Total liabilities

46,999

55,406

Shareholders' Equity

Preferred stock

180

193

Common stock

439

438

Additional

paid-in capital

67,426

67,098

Employee

benefit trust, at fair value

(1,052)

(1,229)

Treasury stock

(39,272)

(35,992)

Retained

earnings

36,446

35,492

Accumulated

other comprehensive income

1,161

2,278

Total shareholders' equity

65,328

68,278

Total liabilities and shareholders'

equity

112,327

123,684

* Unaudited.

** Condensed from audited

financial statements.

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER INC AND

SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

(UNAUDITED)

Six Months Ended

(millions

of dollars)

July 3,

2005

June 27,

2004

Operating Activities:

Net income

3,763

5,195

Adjustments to reconcile net income to net cash

provided by continuing operating activities:

Discontinued operations - net of tax

(19)

(32)

Depreciation and amortization

2,776

2,517

Merger-related in-process research and development

charges

262

955

Asset impairment charge and other costs associated

with the suspension of Bextra sales

1,213

--

Deferred taxes

(127)

(222)

Other

49

463

Changes in assets and liabilities (net of businesses

acquired and divested)

(934)

(3,702)

Net

cash provided by continuing operating activities

6,983

5,174

Investing

Activities:

Purchases of property, plant and equipment

(997)

(961)

Purchases of short-term investments

(7,441)

(8,655)

Proceeds from redemptions of short-term investments

12,570

3,242

Purchases of long-term investments

(560)

(712)

Proceeds from sales of long-term investments

568

1,429

Purchases of other assets

(99)

(411)

Proceeds from sales of other assets

225

Acquisition of businesses, net of cash acquired

(255)

(1,443)

Proceeds from the sales of businesses and product

lines

101

575

Other investing activities

276

(59)

Net

cash provided by/(used in) investing activities

4,169

(6,770)

Financing

Activities:

Increase in short-term borrowings, net

90

3,360

Principal payments on short-term borrowings

(5,800)

(170)

Proceeds from issuances of long-term debt

1,588

Principal payments on long-term debt

(22)

(11)

Proceeds from common stock issuances

33

37

Purchases of common stock

(3,304)

(2,275)

Cash dividends paid

(2,930)

(2,562)

Stock option transactions and other

245

749

Net cash (used in)/provided by financing activities

(11,686)

716

Effect of exchange-rate changes on cash and cash

equivalents

12

Net decrease in cash and cash equivalents

(532)

(868)

Cash and cash equivalents at beginning of period

1,808

1,520

Cash and cash equivalents at end of period

1,276

652

Supplemental Cash Flow Information:

Cash paid during the period for:

Income taxes

1,296

1,853

Interest

329

194

Non-cash transaction:

Receivable from sale of business (received on

June 28, 2004)

--

450

See accompanying

Notes to Condensed Consolidated Financial Statements.

PFIZER

INC AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1: Basis of Presentation

General

We prepared the condensed consolidated financial statements

following the requirements of the Securities and Exchange Commission (SEC) for

interim reporting. As permitted under those rules, certain footnotes or other

financial information that are normally required by accounting principles

generally accepted in the United States of America (GAAP) can be condensed or

omitted. Balance sheet amounts and operating results for subsidiaries operating

outside the U.S. are as of and for the three-month and six-month periods ended May 29,

2005 and May 23, 2004. The fiscal first quarter and six months of 2005 had

three additional business days compared to the fiscal first quarter and six

months of 2004.

We made certain reclassifications to the 2004 condensed

consolidated financial statements to conform to the 2005 presentation.

Revenues, expenses, assets and liabilities can vary during

each quarter of the year. Therefore, the results and trends in these interim

financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements

included in this document. The financial statements include all normal and

recurring adjustments that are considered necessary for the fair presentation

of our financial position and operating results.

The information included in this Quarterly Report on

Form 10-Q should be read in conjunction with the consolidated financial

statements and accompanying notes included in Pfizer's Annual Report on

Form 10-K for the year ended December 31, 2004.

Share-Based Payments

In accordance with Statement of Financial Accounting

Standards (SFAS) No. 123, Accounting for Stock-Based Compensation, we

elect to account for our stock-based compensation under Accounting Principles

Board Opinion No. 25, Accounting for Stock Issued to Employees. The

exercise price of stock options granted equals the market price on the date of

grant; therefore, there is no recorded compensation expense related to grants

of stock options.

The weighted-average fair value

per stock option granted was $3.23 and $4.49 for the three months ended July 3,

2005 and June 27, 2004 and $5.15 and $6.88 for the six months ended

July 3, 2005 and June 27, 2004. We estimated the fair values, as

required under GAAP, using the Black-Scholes option-pricing model, modified for

dividends and using the assumptions below. Pro forma compensation expense

related to stock options subject to accelerated vesting upon retirement is

recognized over the period of employment up to the vesting date of the grant.

In the first quarter of 2005, we changed our method of estimating expected

dividend yield from historical patterns of dividend payments to a method that

reflects a constant dividend yield during the expected term of the option.

Three Months Ended

Six Months Ended

July 3,

2005

June 27,

2004

July 3,

2005

June 27,

2004

Expected dividend yield

2.72%

2.57%

2.90%

2.90%

Risk-free interest rate

3.75%

2.07%

3.96%

3.32%

Expected stock price volatility

16.90%

20.43%

21.93%

22.15%

Expected term until exercise

(years)

2.75

3.26

5.75

5.75

The following table shows the

effect on results for the three-month and six-month periods ended July 3,

2005 and June 27, 2004 if we had applied the fair-value-based recognition

provisions of SFAS 123 to measure stock-based compensation expense for the

option grants:

Three

Months Ended

Six

Months Ended

(millions

of dollars, except per common share data)

July 3,

2005

June 27,

2004

July 3,

2005

June 27,

2004

Net income

available to common shareholders used in the calculation of basic earnings

per common share:

As reported

under GAAP*

3,461

2,862

3,761

5,193

Compensation

expense - net of tax

(104)

(147)

(252)

(273)

Pro forma

3,357

2,715

3,509

4,920

Basic earnings

per common share:

As reported

under GAAP*

.47

.38

.51

.69

Compensation

expense - net of tax

(.01)

(.02)

(.04)

(.04)

Pro forma

.46

.36

.47

.65

Net income

available to common shareholders used in the calculation of diluted earnings

per common share:

As reported

under GAAP*

3,461

2,862

3,761

5,192

Compensation

expense - net of tax

(104)

(147)

(252)

(273)

Pro forma

3,357

2,715

3,509

4,919

Diluted

earnings per common share:

As reported

under GAAP*

.47

.38

.51

.68

Compensation

expense - net of tax

(.02)

(.02)

(.04)

(.04)

Pro forma

.45

.36

.47

.64

Includes

stock-based compensation expense, net of related tax benefits, of $53 million

for the six months ended July 3, 2005 ($38 million for the three

months ended July 3, 2005) and $40 million for the six months ended

June 27, 2004 ($10 million for the three months ended June 27,

2004).

Net income available to common shareholders used in the

calculation of basic earnings per common share represents net income reduced by

preferred stock dividends - net of tax. Net income available to

common shareholders used in the calculation of diluted earnings per common share

represents net income reduced by the incremental allocation of shares to the

Employee Stock Ownership Plans (ESOPs) acquired as part of the Pharmacia

acquisition.

Note 2: Asset Impairment Charge and Other

Costs Associated with the Suspension of Bextra Sales

In the first six months of 2005, we recorded charges

totaling $1.2 billion ($761 million, net of tax) in connection with the

decision to suspend sales and marketing of Bextra. This decision resulted from

an April 7, 2005 request from the U.S. Food and Drug Administration (FDA),

as part of its safety review of all COX-2 medicines.

The pre-tax charges included

$1.1 billion related to the impairment of developed technology rights

associated with Bextra and $7 million related to the write-off of

machinery and equipment, both of which are included in Other

(income)/deductions - net. In addition, in connection with the

suspension, we also recorded $56 million in write-offs of inventory and

exit costs, included in Cost of sales; $5 million related to the

costs of administering the suspension of sales, included in Selling,

informational and administrative expenses; and $173 million, for an

estimate of customer returns, primarily included against Revenues.

Substantially all of these charges were recorded in the first quarter of 2005.

Note 3: Income Taxes

Income Tax Charge Associated with Repatriation Decision

In the first six months of 2005, we recorded an income tax

charge of $1.7 billion, included in (Benefit)/provision for

taxes on income, in connection with our decision to repatriate about $36.7 billion

of foreign earnings in accordance with the American Jobs Creation Act of

2004 (the Jobs Act). In the first quarter of 2005, we recorded an initial

estimated income tax charge of $2.2 billion based on the decision to

repatriate $28.3 billion of foreign earnings; in the second quarter of

2005, we reduced our original estimate of the tax charge by $863 million

and revised the repatriation of foreign earnings to $28.1 billion,

principally as a result of guidance issued by the U.S. Treasury in May 2005. In

the second quarter of 2005, we also recorded an additional tax charge of $373 million,

primarily due to our decision to repatriate an additional $8.6 billion of

foreign earnings.

As of July 3, 2005, we intend to continue to reinvest

the earnings of our international subsidiaries and, therefore, we have not

recorded a U.S. tax provision on the remaining amount of unremitted earnings.

Tax Contingencies

In the second quarter of 2005, we recorded a tax benefit of

$586 million primarily related to the resolution of certain tax positions.

We believe that the IRS audits of the Pfizer Inc. tax returns for the years

1999-2001 and the Warner-Lambert Company tax returns for the years 1999 through

the date of the merger with Pfizer (June 19, 2000) are substantially

complete. In connection with those audits, we are currently in the process of

appealing one matter related to the tax deductibility of a breakup fee paid by

Warner-Lambert Company in 2000.

The IRS has commenced the audit of the Pfizer Inc. tax returns

for the years 2002 and 2003. The 2005 tax year is also currently under audit.

As previously disclosed, with respect to Pharmacia

Corporation (formerly known as Monsanto Company), the IRS has completed and

closed its income tax return examinations and appeals through 1999 and has

commenced the audit of the tax returns for the years 2000 through the date of

merger with Pfizer (April 16, 2003).

We periodically reassess the likelihood of assessments

resulting from audits of federal, state and foreign income tax filings. We

believe that our accruals for tax liabilities are adequate for all open years.

Note 4: Adapting to Scale Initiative

We recently launched a company-wide initiative, called

Adapting to Scale (AtS), which involves a comprehensive review of our

processes, organizations, systems and decision making. In the second quarter of

2005, in connection with this AtS initiative, we incurred and paid approximately

$21 million in restructuring charges, primarily related to employee

termination costs at our manufacturing facilities located in North America. We

also incurred and paid approximately $33 million in implementation costs,

included in Cost of sales ($1 million), Selling, informational

and administrative expenses ($21 million) and Research and

development expenses ($11 million), primarily related to system and

process standardization and the expansion of shared services.

We now expect the costs associated with this multi-year

effort to continue through 2008 and to total approximately $4 billion to